Cereno Scientific nominates drug candidate CS014 in HDACi Program for continued development in cardiovascular disease
Cereno Scientific (XSAT: CRNO B) today announced the nomination of drug candidate CS014 for continued development in the preclinical HDACi (histone deacetylase inhibitor) Program. After completing the first half of the preclinical development program, CS014 was nominated after demonstrating highest potential in cardiovascular disease among a set of similar molecules. CS014 is being developed with the aim to provide a better treatment for patients with cardiovascular disease.“It is great to announce that we have made good advancement in the preclinical HDACi Program, resulting in the